Catalent and Exelixis Link on ADCs

US-based CDMO Catalent is joining forces with compatriot drug discovery company Exelixis to develop multiple antibody-drug conjugates (ADCs). The company’s Redwood Bioscience subsidiary will use its proprietary SMARTag site-specific bioconjugation technology to build ADCs using monoclonal antibodies from Exelixis’ preclinical pipeline.

In exchange for an upfront payment of $10 million, Exelixis has received an exclusive option to nominate up to a fixed number of targets using the SMARTag ADC platform over a three-year period.

The companies plan to advance the ADCs into preclinical development. Prior to filing an Investigational New Drug application, Exelixis may exercise an exclusive option for a worldwide license of the ADC program and continue clinical development and commercialization. It will also provide funding for R&D. Catalent will be eligible for development and commercial milestones plus royalties on net sales of any product that is commercialized as part of the partnership.

“Our collaboration with Catalent – the fifth pipeline-enhancing agreement we’ve signed since 2018 – provides an attractive framework for identifying and advancing differentiated ADC product candidates with the potential to improve upon current ADC therapies,” said Peter Lamb, executive vice president, scientific strategy and chief scientific officer at Exelixis. “We are looking forward to working with Catalent as we rapidly advance our mission to help cancer patients recover stronger and live longer.”

Mike Riley, Catalent Biologics’ region president, North America, added that the SMARTag platform has recently demonstrated promising results in the clinic, which he said highlighted its potential to create ADCs with significantly expanded therapeutic indices.

The CDMO has been busy elsewhere, announcing plans for two separate projects to add capacity in the US. Some $130 million will be spent on five additional suites for phase 3- through-commercialization at its gene therapy campus in Harmans, Maryland, by the first half of 2022. In another project, it will spend $50 million to install an extra high-speed vial filling line at its site in Bloomington, Indiana by April 2021.

 

Author: Elaine Burridge, Freelance Journalist

Catalent is joining forces on antibody-drug conjugates (ADCS) with Exelixis....
Catalent is joining forces on antibody-drug conjugates (ADCS) with Exelixis. Catalent’s Redwood Bioscience subsidiary will use its proprietary SMARTag site-specific bioconjugation technology to build multiple ADCs using monoclonal antibodies from Exelixis’ preclinical pipeline.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read